Publications
327 results found
Crosbie EJ, Edmondson RJ, McNeish IA, et al., 2015, Are rigid management protocols stifling innovation in cancer treatment?, BJOG, Vol: 122, Pages: 1432-1434
Kristeleit R, Swisher E, Oza A, et al., 2015, Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis, European Cancer Congress, Publisher: ELSEVIER SCI LTD, Pages: S531-S531, ISSN: 0959-8049
- Author Web Link
- Cite
- Citations: 15
Spiliopoulou P, Gibson S, Davidson R, et al., 2015, Routine germline BRCA testing in serous ovarian cancer: The West of Scotland experience, European Cancer Congress, Publisher: ELSEVIER SCI LTD, Pages: S554-S554, ISSN: 0959-8049
Lawrenson K, Li Q, Kar S, et al., 2015, <i>Cis</i>-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer, NATURE COMMUNICATIONS, Vol: 6, ISSN: 2041-1723
- Author Web Link
- Cite
- Citations: 41
Kelemen LE, Lawrenson K, Tyrer J, et al., 2015, Genome-wide significant risk associations for mucinous ovarian carcinoma, NATURE GENETICS, Vol: 47, Pages: 888-897, ISSN: 1061-4036
- Author Web Link
- Cite
- Citations: 68
Oza AM, Cook AD, Pfisterer J, et al., 2015, Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial, LANCET ONCOLOGY, Vol: 16, Pages: 928-936, ISSN: 1470-2045
- Author Web Link
- Cite
- Citations: 553
Browne A, Tookman LA, Ingemarsdotter CK, et al., 2015, Pharmacological Inhibition of β<sub>3</sub> Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity, CANCER RESEARCH, Vol: 75, Pages: 2811-2821, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 9
Coetzee SG, Shen HC, Hazelett DJ, et al., 2015, Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci, HUMAN MOLECULAR GENETICS, Vol: 24, Pages: 3595-3607, ISSN: 0964-6906
- Author Web Link
- Cite
- Citations: 34
Chornokur G, Lin H-Y, Tyrer JP, et al., 2015, Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk, PLOS ONE, Vol: 10, ISSN: 1932-6203
- Author Web Link
- Cite
- Citations: 15
Hughes J, Wang P, Alusi G, et al., 2015, Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus, GENE THERAPY, Vol: 22, Pages: 476-484, ISSN: 0969-7128
- Author Web Link
- Cite
- Citations: 18
Spiliopoulou P, Gibson S, Davidson R, et al., 2015, Routine germline BRCA testing in serous ovarian cancer: The West of Scotland experience., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 1
Wilson MK, Lin K, McNeish IA, et al., 2015, Tumor biopsies in high grade ovarian cancer: Clinical utility and challenges for biomarker-directed therapy., 51st Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
McNeish IA, Michael A, Twelves C, et al., 2015, A phase I/II study of Enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intraperitoneally (IP): Dose finding and proof of concept in platinum-resistant epithelial ovarian cancer., Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 2
McNeish IA, Oza AM, Coleman RL, et al., 2015, Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis., 51st Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 21
Ingemarsdotter CK, Tookman LA, Browne A, et al., 2015, Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control, MOLECULAR ONCOLOGY, Vol: 9, Pages: 791-805, ISSN: 1574-7891
- Author Web Link
- Cite
- Citations: 29
Lee AW, Tyrer JP, Doherty JA, et al., 2015, Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study, GYNECOLOGIC ONCOLOGY, Vol: 136, Pages: 542-548, ISSN: 0090-8258
- Author Web Link
- Cite
- Citations: 13
Kuchenbaecker KB, Ramus SJ, Tyrer J, et al., 2015, Identification of six new susceptibility loci for invasive epithelial ovarian cancer, NATURE GENETICS, Vol: 47, Pages: 164-171, ISSN: 1061-4036
- Author Web Link
- Cite
- Citations: 179
Jim HSL, Lin H-Y, Tyrer JP, et al., 2015, Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC)., J Genet Genome Res, Vol: 2, ISSN: 2378-3648
Disruption in circadian gene expression, whether due to genetic variation or environmental factors (e.g., light at night, shiftwork), is associated with increased incidence of breast, prostate, gastrointestinal and hematologic cancers and gliomas. Circadian genes are highly expressed in the ovaries where they regulate ovulation; circadian disruption is associated with several ovarian cancer risk factors (e.g., endometriosis). However, no studies have examined variation in germline circadian genes as predictors of ovarian cancer risk and invasiveness. The goal of the current study was to examine single nucleotide polymorphisms (SNPs) in circadian genes BMAL1, CRY2, CSNK1E, NPAS2, PER3, REV1 and TIMELESS and downstream transcription factors KLF10 and SENP3 as predictors of risk of epithelial ovarian cancer (EOC) and histopathologic subtypes. The study included a test set of 3,761 EOC cases and 2,722 controls and a validation set of 44,308 samples including 18,174 (10,316 serous) cases and 26,134 controls from 43 studies participating in the Ovarian Cancer Association Consortium (OCAC). Analysis of genotype data from 36 genotyped SNPs and 4600 imputed SNPs indicated that the most significant association was rs117104877 in BMAL1 (OR = 0.79, 95% CI = 0.68-0.90, p = 5.59 × 10-4]. Functional analysis revealed a significant down regulation of BMAL1 expression following cMYC overexpression and increasing transformation in ovarian surface epithelial (OSE) cells as well as alternative splicing of BMAL1 exons in ovarian and granulosa cells. These results suggest that variation in circadian genes, and specifically BMAL1, may be associated with risk of ovarian cancer, likely through disruption of hormonal pathways.
Browne AK, Tookman LA, Ingemarsdotter CK, et al., 2014, Beta-3 integrin inhibition reduces inflammatory cytokine release but not anti-cancer activity of oncolytic adenovirus in ovarian cancer, 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Publisher: ELSEVIER SCI LTD, Pages: 38-38, ISSN: 0959-8049
Okamoto A, Glasspool RM, Mabuchi S, et al., 2014, Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary, INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, Vol: 24, Pages: S20-S25, ISSN: 1048-891X
- Author Web Link
- Cite
- Citations: 95
McNeish I, Coleman RL, Oza A, et al., 2014, UPDATED RESULTS OF ARIEL2, A PHASE 2 OPEN-LABEL STUDY TO IDENTIFY OVARIAN CANCER PATIENTS LIKELY TO RESPOND TO RUCAPARIB, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: 323-324, ISSN: 1048-891X
- Author Web Link
- Cite
- Citations: 1
Swisher E, Brenton J, Kaufmann S, et al., 2014, Updated clinical and preliminary correlative results of ARIEL2, a Phase 2 study to identify ovarian cancer patients likely to respond to rucaparib, 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Publisher: ELSEVIER SCI LTD, Pages: 73-73, ISSN: 0959-8049
- Author Web Link
- Cite
- Citations: 6
McNeish IA, Ledermann JA, Webber L, et al., 2014, A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, ANNALS OF ONCOLOGY, Vol: 25, Pages: 1988-1995, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 64
Hook J, Stenning SP, Brenton J, et al., 2014, ICON8: An international randomized trial comparing two dose dense regimens, 3-weekly carboplatin plus weekly paclitaxel (CwT), and weekly carhoplatin-paclitaxel (wCwT), to standard 3-weekly treatment in women with newly diagnosed ovarian, fallopian tube, and primary peritoneal cancer, 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 3
Swisher EM, McNeish IA, Coleman RL, et al., 2014, ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response., 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 3
Rockall AG, Avril N, Lam R, et al., 2014, Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: Test-retest measurements for tumor FDG uptake, diameter, and volume, Clinical Cancer Research, Vol: 20, Pages: 2751-2760, ISSN: 1078-0432
Purpose: Repeatability of baseline FDG-PET/CT measurements has not been tested in ovarian cancer. This dual-center, prospective study assessed variation in tumor 2[18F]fluoro-2-deoxy-D-glucose (FDG) uptake, tumor diameter, and tumor volume from sequential FDG-PET/CT and contrast-enhanced computed tomography (CECT) in patients with recurrent platinum-sensitive ovarian cancer.Experimental Design: Patients underwent two pretreatment baseline FDG-PET/CT (n = 21) and CECT (n = 20) at two clinical sites with different PET/CT instruments. Patients were included if they had at least one target lesion in the abdomen with a standardized uptake value (SUV) maximum (SUVmax) of ≥2.5 and a long axis diameter of ≥15 mm. Two independent reading methods were used to evaluate repeatability of tumor diameter and SUV uptake: on site and at an imaging clinical research organization (CRO). Tumor volume reads were only performed by CRO. In each reading set, target lesions were independently measured on sequential imaging.Results: Median time between FDG-PET/CT was two days (range 1–7). For site reads, concordance correlation coefficients (CCC) for SUVmean, SUVmax, and tumor diameter were 0.95, 0.94, and 0.99, respectively. Repeatability coefficients were 16.3%, 17.3%, and 8.8% for SUVmean, SUVmax, and tumor diameter, respectively. Similar results were observed for CRO reads. Tumor volume CCC was 0.99 with a repeatability coefficient of 28.1%.Conclusions: There was excellent test–retest repeatability for FDG-PET/CT quantitative measurements across two sites and two independent reading methods. Cutoff values for determining change in SUVmean, SUVmax, and tumor volume establish limits to determine metabolic and/or volumetric response to treatment in platinum-sensitive relapsed ovarian cancer.
Glasspool RM, Brown R, Gore ME, et al., 2014, A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2 '-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer, British Journal of Cancer, Vol: 110, Pages: 1923-1929, ISSN: 1532-1827
Background: Our previous laboratory and clinical data suggested that one mechanism underlying the development of platinum resistance inovarian cancer is the acquisition of DNA methylation. We therefore tested the hypothesis that the DNA hypomethylating agent 5-aza-20-deoxycytodine (decitabine) can reverse resistance to carboplatin in women with relapsed ovarian cancer.Methods: Patients progressing 6–12 months after previous platinum therapy were randomised to decitabine on day 1 and carboplatin (AUC 6) onday 8, every 28 days or carboplatin alone. The primary objective was response rate in patients with methylated hMLH1 tumour DNA in plasma.Results: After a pre-defined interim analysis, the study closed due to lack of efficacy and poor treatment deliverability in 15 patients treated withthe combination. Responses by GCIG criteria were 9 out of 14 vs 3 out of 15 and by RECIST were 6 out of 13 vs 1 out of 12 for carboplatin andcarboplatin/decitabine, respectively. Grade 3/4 neutropenia was more common with the combination (60% vs 15.4%) as was G2/3 carboplatinhypersensitivity (47% vs 21%).Conclusions: With this schedule, the addition of decitabine appears to reduce rather than increase the efficacy of carboplatin in partiallyplatinum-sensitive ovarian cancer and is difficult to deliver. Patient-selection strategies, different schedules and other demethylating agents shouldbe considered in future combination studies.
Glasspool RM, McNeish IA, 2013, Clear Cell Carcinoma of Ovary and Uterus, CURRENT ONCOLOGY REPORTS, Vol: 15, Pages: 566-572, ISSN: 1523-3790
- Author Web Link
- Cite
- Citations: 29
Whilding LM, Archibald KM, Kulbe H, et al., 2013, Vaccinia Virus Induces Programmed Necrosis in Ovarian Cancer Cells, MOLECULAR THERAPY, Vol: 21, Pages: 2074-2086, ISSN: 1525-0016
- Author Web Link
- Cite
- Citations: 49
Leinster DA, Colom B, Whiteford JR, et al., 2013, Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer, FASEB JOURNAL, Vol: 27, Pages: 4244-4253, ISSN: 0892-6638
- Author Web Link
- Cite
- Citations: 16
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.